Abstract
The ability to control T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to improve safety. Here, we describe the development of a new CAR architecture with an integrated switch-on system that permits to control the CAR T-cell function. This system offers the advantage of a transient CAR T-cell for safety while letting open the possibility of multiple cytotoxicity cycles using a small molecule drug.
MeSH terms
-
CD8 Antigens / genetics
-
CD8 Antigens / immunology
-
Cell Line, Tumor
-
Coculture Techniques
-
Cytotoxicity, Immunologic / drug effects*
-
Gene Expression
-
Genetic Engineering / methods*
-
Genetic Vectors / chemistry
-
Genetic Vectors / immunology
-
Humans
-
Mutant Chimeric Proteins / genetics*
-
Mutant Chimeric Proteins / immunology
-
Protein Domains
-
Receptors, Antigen, T-Cell / genetics*
-
Receptors, Antigen, T-Cell / immunology
-
Single-Chain Antibodies / genetics
-
Sirolimus / analogs & derivatives
-
Sirolimus / pharmacology
-
T-Lymphocytes / cytology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology*
-
Tacrolimus / pharmacology
-
Transfection
Substances
-
AP 21967
-
CD8 Antigens
-
CD8 antigen, alpha chain
-
Mutant Chimeric Proteins
-
Receptors, Antigen, T-Cell
-
Single-Chain Antibodies
-
Sirolimus
-
Tacrolimus